• FibroBiologics released a third batch of CYWC628 for its Phase 1/2 diabetic foot ulcer trial, supporting continued dosing at Australian sites.
• CYWC628 is a topical allogeneic fibroblast cell therapy being tested alongside standard care versus standard care alone.
• Results have not been presented; statistically significant interim primary outcome data are expected in the second half of 2026.
• Early progress in the ongoing study was described as encouraging, pointing to potential clinical benefit if confirmed in interim readouts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608270830PR_NEWS_USPR_____DA34861) on August 27, 2026, and is solely responsible for the information contained therein.